Connect with us

Features

Can metastasis prevention save breast cancer patients?

Published

on

Femtech World meets the Swiss company on a mission to enable optimal breast cancer treatment and make lasting metastasis prevention a reality.

Breast cancer is the most common cancer in the UK and the second most common in the US after skin cancer. The American Cancer Society suggests that in 2022 about 287,850 new cases will be diagnosed in women and other 43,250 women will die from breast cancer.

Additionally, studies have shown that an increasing number of patients are not getting the right treatment during therapy.

“Despite molecularly precise cancer tests, we have a situation where more than 50 per cent of the women diagnosed with breast cancer [in the US and Europe] are either under-treated or over-treated,” says Wolfgang Hackl, oncology scientist and founder of OncoGenomX – a Switzerland-based company that aims to create a treatment guidance software against breast cancer.

Their first product, PredictionStar, uses AI and machine learning algorithms to determine the correct cancer treatment regimen for permanent prevention metastasis. The tool essentially interprets the results of clinical and histological image assessments, tumour and blood gene tests and helps oncologists to find the optimal treatment with predictable outcomes.

“The solution that we have developed consists of four components,” Hackl explains. “Firstly, proprietary markers help us to type individual tumours and based on diagnostic properties. Then we have two types of AI-based software: one meant to achieve individualised drug-tumour matching and the other used to make outcome predictions. Lastly, we have a feedback learning solution for the continuous refinement of PredictionStar-guided therapy decision guidance.

“But we don’t leave things at predictions,” the oncologist adds. “We offer the decision-makers real-world outcome data, so that they don’t need to rely on predictions coming out of a black box. They can see recent clinical data from patients who have been treated, based on PredictionStar guidance, what the outcome was and then, they can make an informed decision.”

Hackl says that this is a move from a very “mouse-centric approach”. “We’ve been very good at mice and drug development, but not necessarily at curing patients,” he tells me.

“Current tests are very good at determining, whether a tumour is eligible for certain treatments. These tests, however, cannot predict, whether treatments will also be effective. PredictionStar predicts the effectiveness of treatments with an accuracy of 85 per cent, thus, taking oncology a step closer to the theoretical ideal of evidence-based precision cancer treatment.

“Currently, doctors and patients can learn if the tumour will be eliminated only during the treatment journey,” he continues. “The longer the tumour stays away, the higher the confidence in the treatment decision.

“The advantage of our approach is that doctors and patients would know that there’s a significant high chance the treatment will be effective before the start of the therapy, taking away the uncertainty and the randomness of treatment decisions. Imagine what this would mean for the quality of life of patients.”

Determining the optimal treatment option will not only reduce the risks of over or under-treatment for patients, but it will also diminish the costs on healthcare systems.

“Per year Europe and the US spend over $20B on breast cancer treatment. We are at the very beginning, but we think that consistent use of PredictionStar will incur significant cost savings,” Hackl points out.

The founder adds that: “In one year and a half from now we hope we’ll be ready to offer our services to pharmaceutical companies and drug developers and in two years, if everything goes by plan, we should be in a position to offer the service to cancer hospitals.”

However, stigma around medical patient data still exists. Scepticism about the supposed benefits of data sharing, fear of being disadvantaged and little confidence in data security are just a few of the reasons why some patients avoid such platforms.

“This is certainly something we still see in many countries,” says Hackl. “But we, as a company, never see the data. It will only be exposed to the algorithm. This is a very conventional approach which is used with great success and meets the requirements for the protection of data rights.

“Artificial intelligence and machine learning are widely recognised as a transformative healthcare innovation. However, unless introduced thoughtfully there are risks such as automation bias and over-dependence, in addition to already well-documented generic risks associated with AI, such as data privacy, algorithmic biases and corrigibility,” he continues. “We are fully aware of these risks and will undertake adequate measures to ensure that clinicians retain autonomy over the diagnostic and therapy decision making processes.”

The company has already analysed data from more than 4,500 patients and four trials and has very high ambitions for the future. “We are very confident and we hope to get one step closer to the theoretical ideal of what it means to practice precision diagnosis and medicine as the core of personalised cancer care,” adds Hackl.

“But in the medical area, you always have to prove that your claims are the results of a well-designed, prospective clinical trial. And that’s why we’re here for.”

For more information, visit oncogenomx.ch.

Features

New research centre aims to tackle gender health gap

Published

on

Wales has opened its first women’s health research centre, backed by £3m to tackle health inequalities through research and innovation.

The centre, led by Women’s Health Research Wales, marks the first anniversary of the Women’s Health Plan for Wales, published in December 2024.

First minister Eluned Morgan and minister for mental health and wellbeing Sarah Murphy visited staff, researchers and collaborating communities at the launch.

The work covers prevention, early-onset conditions, rare diseases and care for under-served communities.

The centre brings together researchers, NHS partners, industry, policy makers and communities to develop more effective treatments and ensure services meet women’s needs throughout their lives.

It is designed to strengthen investment in women’s health research, including representation in clinical trials.

Morgan said: “I am passionate about improving women’s healthcare.

“To do that, we must invest in research to gather the evidence we need.

Morgan added: “I am delighted to see how the Welsh Government’s £3m investment, through Health and Care Research Wales, is supporting research based on the experiences of women.

“This will result in better care and better health outcomes for women.”

Projects in development include exploring symptom reporting tools to help manage conditions such as diabetes, heart failure and chronic obstructive pulmonary disease.

Researchers are also investigating how chemicals in menstrual products might affect health, ways to help young people stay active during periods, and pathways to prevent people with polycystic ovary syndrome developing conditions like diabetes and heart disease later in life.

Other projects are exploring fertility issues, including a decision-making tool for women with kidney disease considering whether to have children.

One project is working with women undergoing fertility treatment, investigating why this can lead to mental health issues such as PTSD (post-traumatic stress disorder), with the aim of creating guidance for trauma-informed fertility care.

Morgan said: “This innovative new research centre is a key part of the Women’s Health Plan and will help us better understand women’s experiences.

“It will lead to more effective treatments and make sure that our health service delivers improved outcomes for women in Wales.”

Debbie Shaffer is founder and director of Fair Treatment for the Women of Wales and chair of Women’s Health Wales Coalition.

Shaffer said: “Research into health issues experienced by women throughout the life course is vital.

“By working co-productively, in partnership with women and communities, we have a fantastic opportunity to reduce health inequalities and improve treatment options and support.

“We look forward to helping facilitate more opportunities for those with lived experience, whose voices may not have been heard before, to get involved.”

Continue Reading

Features

Early prenatal support cuts postpartum depression by over 80%, study finds

Published

on

Early pregnancy therapy can cut postpartum depression and anxiety by tackling prenatal anxiety, new research has revealed.

A trial of 1,200 pregnant women in Pakistan found those receiving cognitive behavioural therapy (CBT), a talking therapy that changes patterns of thought and behaviour, had 81 per cent lower odds of postpartum depression or moderate-to-severe anxiety than those receiving usual care.

Only 12 per cent of women in the intervention group developed postpartum depression, compared with 41 per cent in the control group.

The research was led by Pamela Surkan at Johns Hopkins University, in partnership with the University of Liverpool and the Human Development Research Foundation Pakistan.

Surkan said: “We hope this research doesn’t end with evidence, but with implementation.

“Every pregnant woman deserves the chance to thrive, and mental health must be recognised as a core part of maternal health everywhere.”

Among women who attended five or more sessions, the risk of low birthweight (under 2.5kg) and small-for-gestational-age births (smaller than expected for weeks of pregnancy) decreased by 39 per cent and 32 per cent respectively.

The approach was designed to be scalable: therapy was delivered by trained non-specialist counsellors in a public hospital in Rawalpindi, making it accessible and low-cost for health systems without specialist clinicians.

In Pakistan, up to 49 per cent of pregnant women experience anxiety, yet access to mental health care remains limited.

Prenatal anxiety is rarely addressed in public health systems despite long-term consequences for mothers and children.

What began at a global mental health meeting in Washington DC in 2012 evolved into a research partnership spanning 2017 to 2024. Findings from the main trial were published in March 2024.

Beyond clinical outcomes, the research linked better social support, reduced stress and fewer pregnancy-related difficulties to improved mental health outcomes.

To date, 29 peer-reviewed articles have been published from the project, which has established one of the world’s largest datasets on prenatal anxiety in low and middle-income countries and developed an intervention manual ready for wider use.

The team is now focused on scaling, with proposals submitted to test the intervention in new contexts and plans to make the manual publicly available.

Continue Reading

Features

Menstruation linked to longer football injury recovery

Published

on

Football injuries during periods are more severe and take longer to heal, though menstruation does not itself raise injury rates, according to new research.

The study monitored 33 elite players competing in Spain’s top women’s football league over four seasons, from 2019/20 to 2022/23, tracking self-reported menstrual cycle data alongside injury records.

The research was led by Dr Eva Ferrer, who specialises in sports medicine at Sant Joan de Déu Hospital and is a female health specialist at the Barça Innovation Hub in Barcelona.

“We show that menstruation itself does not increase how often injuries happen,” said Ferrer.

“Although athletes were not injured more often during their period, the injuries that happened during menstruation caused three times more days lost than injuries occurring at other times of the cycle.”

Players logged bleeding and non-bleeding days, the only phases of the menstrual cycle that can be reliably identified without blood hormone testing.

A total of 852 menstrual cycles and 80 lower limb injuries were recorded, 11 of which occurred during menstrual bleeding phases.

The findings showed that injury burden was significantly higher during bleeding phases.

The burden of soft tissue injuries, affecting muscles, tendons and ligaments, was more than three times as high when injuries were sustained during bleeding days compared to non-bleeding days, with 684 versus 206 days lost per 1,000 training hours respectively.

“Hormonal levels may not cause the injury, but they may influence how severe the injury becomes and how long recovery takes,” Ferrer explained.

Low oestrogen levels may reduce muscle repair, while increased fatigue, pain and poor sleep can alter neuromuscular control.

Iron loss can lower endurance and slow recovery, and inflammation heightened during menstruation may cause worse tissue damage.

“Small modifications such as longer warm-ups, adjusted high-speed workload, or added recovery support may help reduce the severity of injuries if they occur,” Ferrer said.

The researchers said their findings have implications beyond professional football for women who exercise regularly.

“You do not necessarily need to avoid training during your period, but you may need to adapt it,” Ferrer said.

“Tracking your cycle and symptoms can help guide training intensity and recovery strategies.”

The study’s limitations include all participants belonging to the same club, the unequal number of bleeding and non-bleeding days in a cycle potentially limiting statistical power, and the absence of hormone measurements or data on external factors such as stress, sleep and nutrition.

“It supports a growing movement toward female-specific sports science instead of applying male-based research models to women,” Ferrer concluded.

Continue Reading

Trending

Copyright © 2025 Aspect Health Media Ltd. All Rights Reserved.